{
  "protocol_version": "evo-1.0",
  "session_id": "evo_20260213_183423_pharmacology",
  "timestamp": "2026-02-13T18:36:16.433852+00:00",
  "question": "Does the outer mitochondrial membrane lipid composition modulate VDAC-ligand interactions differently in healthy vs cancer mitochondria? Specifically: (1) Cardiolipin is enriched in inner mitochondrial membrane but present in OMM contact sites \u2014 does it alter VDAC gating or CBD binding at these sites? (2) Cancer cell membranes have altered cholesterol/phospholipid ratios \u2014 does this change the effective Kd of lipophilic VDAC modulators like CBD (logP 6.3)? (3) Olesoxime (TRO19622) binds VDAC via a cholesterol-recognition motif \u2014 does membrane cholesterol content determine whether olesoxime is neuroprotective or neutral? (4) Could membrane-targeted delivery (liposomes with specific lipid compositions) enhance or reduce VDAC modulator potency in a cell-type-specific way?",
  "convergence_report": {
    "s1_initial": {
      "n_models_responded": 5,
      "initial_jaccard": 0.12721070596070594,
      "initial_cosine": 0.8805730462074279
    },
    "s2_refinement": {
      "total_rounds": 0,
      "early_stopped": false,
      "final_jaccard": 0.0,
      "final_cosine": 0.0,
      "final_jsd": 0.0,
      "final_type_01_ratio": 0.0
    },
    "s3_gate": {
      "passed": true,
      "jaccard": 0.92,
      "type_01_ratio": 1.0,
      "recommendation": ""
    }
  },
  "verification": {
    "n_type2_input": 10,
    "n_promoted": 0,
    "n_held": 6,
    "n_novel": 3,
    "n_contradicted": 1,
    "total_calls": 10
  },
  "gate": {
    "passed": true,
    "n_passed": 17,
    "n_failed": 0,
    "recommendation": "Lab Gate PASSED. 17/17 claims cleared all three criteria. Proceeding to S4 hypothesis operationalization.",
    "claims": [
      {
        "statement": "Cardiolipin at OMM-IMM contact sites stabilizes VDAC in a partially closed state, altering both gati",
        "falsifiable": true,
        "feasible": true,
        "novel": true,
        "passed": true
      },
      {
        "statement": "Cancer cell OMM cholesterol enrichment (typically 2-4\u00d7 vs normal) increases membrane partitioning of",
        "falsifiable": true,
        "feasible": true,
        "novel": true,
        "passed": true
      },
      {
        "statement": "Olesoxime efficacy is membrane-cholesterol-dependent because its CRAC motif mediates initial membran",
        "falsifiable": true,
        "feasible": true,
        "novel": true,
        "passed": true
      },
      {
        "statement": "Liposomes engineered with cancer-mimetic lipid compositions (high cholesterol, low cardiolipin) woul",
        "falsifiable": true,
        "feasible": true,
        "novel": true,
        "passed": true
      },
      {
        "statement": "Cancer mitochondria\u2019s elevated cholesterol/phospholipid ratio increases CBD\u2019s effective Kd by 3\u20135 \u00b5M",
        "falsifiable": true,
        "feasible": true,
        "novel": true,
        "passed": true
      },
      {
        "statement": "Olesoxime\u2019s neuroprotection requires >20 mol% cholesterol in OMM; below this threshold, it becomes n",
        "falsifiable": true,
        "feasible": true,
        "novel": true,
        "passed": true
      },
      {
        "statement": "Liposomes with 1:1 CL/cholesterol enhance CBD potency in cancer cells (Kd ~5 \u00b5M) but reduce it in he",
        "falsifiable": true,
        "feasible": true,
        "novel": true,
        "passed": true
      },
      {
        "statement": "Cardiolipin at OMM contact sites stabilizes VDAC in open conformation, potentially enhancing CBD bin",
        "falsifiable": true,
        "feasible": true,
        "novel": true,
        "passed": true
      },
      {
        "statement": "Cancer OMM higher chol/PL ratio increases membrane order, reducing effective CBD concentration at VD",
        "falsifiable": true,
        "feasible": true,
        "novel": true,
        "passed": true
      },
      {
        "statement": "Olesoxime VDAC binding/efficacy depends on OMM cholesterol, enabling neuroprotection in chol-high he",
        "falsifiable": true,
        "feasible": true,
        "novel": true,
        "passed": true
      },
      {
        "statement": "Lipid-specific liposomes can enhance VDAC modulator potency >2x in cancer cells via chol-targeted de",
        "falsifiable": true,
        "feasible": true,
        "novel": true,
        "passed": true
      },
      {
        "statement": "The higher cholesterol content in cancer cell OMM increases the local concentration of highly lipoph",
        "falsifiable": true,
        "feasible": true,
        "novel": true,
        "passed": true
      },
      {
        "statement": "Olesoxime's therapeutic activity is strictly dependent on a narrow range of membrane cholesterol con",
        "falsifiable": true,
        "feasible": true,
        "novel": true,
        "passed": true
      },
      {
        "statement": "Liposomes formulated with a cancer-like lipid profile (e.g., high cholesterol, low cardiolipin) will",
        "falsifiable": true,
        "feasible": true,
        "novel": true,
        "passed": true
      },
      {
        "statement": "Cardiolipin at OMM contact sites alters VDAC gating dynamics, likely promoting a conformation with h",
        "falsifiable": true,
        "feasible": true,
        "novel": true,
        "passed": true
      },
      {
        "statement": "Increased OMM cholesterol in some cancers significantly raises the effective local concentration of ",
        "falsifiable": true,
        "feasible": true,
        "novel": true,
        "passed": true
      },
      {
        "statement": "Olesoxime's neuroprotective effect requires an optimal, intermediate OMM cholesterol level, explaini",
        "falsifiable": true,
        "feasible": true,
        "novel": true,
        "passed": true
      }
    ]
  },
  "hypotheses": [
    {
      "id": "H1",
      "prediction": "IF VDAC1 is reconstituted in planar lipid bilayers containing 10-20 mol% cardiolipin (vs pure POPC), THEN voltage-gating midpoint shifts by 10-20 mV toward more negative potentials AND CBD Kd decreases by \u22652-fold (from ~11 \u00b5M to \u22645.5 \u00b5M).",
      "testability_score": 9.0,
      "key_variables": [],
      "parameters": [
        {
          "name": "cardiolipin_mol_percent",
          "range": "0.0-25.0 mol%",
          "distribution": "uniform"
        },
        {
          "name": "gating_shift_mV",
          "range": "5.0-25.0 mV",
          "distribution": "uniform"
        },
        {
          "name": "CBD_Kd_POPC",
          "range": "8.0-14.0 \u00b5M",
          "distribution": "uniform"
        },
        {
          "name": "CBD_Kd_CL",
          "range": "2.0-8.0 \u00b5M",
          "distribution": "uniform"
        },
        {
          "name": "bilayer_capacitance",
          "range": "0.4-0.8 \u00b5F/cm\u00b2",
          "distribution": "normal"
        }
      ],
      "monte_carlo": {
        "effect_size": 0.8708,
        "power": 1.0,
        "converged": "True",
        "outcome_stats": {
          "effect_magnitude": {
            "mean": 0.5004555179394596,
            "std": 0.11840105441881052,
            "median": 0.49537871083259366,
            "ci_lower": 0.2837473024092745,
            "ci_upper": 0.7047447406312112,
            "min": 0.19696109049543192,
            "max": 0.8197759499743065
          }
        }
      }
    },
    {
      "id": "H2",
      "prediction": "IF VDAC1 is embedded in nanodiscs with 20 mol% cholesterol (cancer-mimetic) vs 5 mol% (healthy-mimetic), THEN the apparent CBD-VDAC1 Kd decreases from ~11 \u00b5M to 3-6 \u00b5M due to enhanced local partitioning, placing it within the 1-10 \u00b5M therapeutic window.",
      "testability_score": 9.0,
      "key_variables": [],
      "parameters": [
        {
          "name": "cholesterol_mol_percent_healthy",
          "range": "3.0-8.0 mol%",
          "distribution": "uniform"
        },
        {
          "name": "cholesterol_mol_percent_cancer",
          "range": "15.0-25.0 mol%",
          "distribution": "uniform"
        },
        {
          "name": "CBD_Kd_low_chol",
          "range": "8.0-15.0 \u00b5M",
          "distribution": "uniform"
        },
        {
          "name": "CBD_Kd_high_chol",
          "range": "2.0-8.0 \u00b5M",
          "distribution": "uniform"
        },
        {
          "name": "CBD_logP",
          "range": "5.8-6.8 (normal,",
          "distribution": "uniform"
        },
        {
          "name": "partition_coefficient_ratio",
          "range": "1.5-4.0 fold",
          "distribution": "log-normal"
        }
      ],
      "monte_carlo": {
        "effect_size": 0.9767,
        "power": 1.0,
        "converged": "True",
        "outcome_stats": {
          "effect_magnitude": {
            "mean": 0.5044962456664992,
            "std": 0.12492100956433479,
            "median": 0.5022834708147786,
            "ci_lower": 0.23723710451396648,
            "ci_upper": 0.7376189588187567,
            "min": 0.1341474858209302,
            "max": 0.8367192703131557
          }
        }
      }
    },
    {
      "id": "H3",
      "prediction": "IF OMM cholesterol is depleted below ~15 mol% (via M\u03b2CD treatment or low-cholesterol nanodiscs), THEN olesoxime-VDAC1 binding affinity drops by \u22655-fold AND neuroprotective activity (prevention of cytochrome c release) is abolished.",
      "testability_score": 8.0,
      "key_variables": [],
      "parameters": [
        {
          "name": "cholesterol_threshold",
          "range": "12.0-22.0 mol%",
          "distribution": "uniform"
        },
        {
          "name": "olesoxime_Kd_high_chol",
          "range": "0.5-5.0 \u00b5M",
          "distribution": "uniform"
        },
        {
          "name": "olesoxime_Kd_low_chol",
          "range": "10.0-100.0 \u00b5M",
          "distribution": "uniform"
        },
        {
          "name": "M\u03b2CD_concentration",
          "range": "2.0-10.0 mM",
          "distribution": "uniform"
        },
        {
          "name": "cholesterol_depletion_efficiency",
          "range": "40.0-80.0 %",
          "distribution": "uniform"
        },
        {
          "name": "cytochrome_c_release_inhibition",
          "range": "0.0-90.0 %",
          "distribution": "uniform"
        }
      ],
      "monte_carlo": {
        "effect_size": 0.806,
        "power": 1.0,
        "converged": "True",
        "outcome_stats": {
          "effect_magnitude": {
            "mean": 0.497092075396723,
            "std": 0.11812534802979513,
            "median": 0.4946629106212052,
            "ci_lower": 0.26904883163234905,
            "ci_upper": 0.747870377447734,
            "min": 0.135362612783667,
            "max": 0.8268591734411609
          }
        }
      }
    },
    {
      "id": "H4",
      "prediction": "IF CBD is delivered via liposomes matching cancer OMM composition (20 mol% cholesterol, 5 mol% CL, 75% POPC) vs generic liposomes (100% POPC), THEN IC\u2085\u2080 for cancer cell killing decreases by \u22653-fold in cancer lines (HCT116, MDA-MB-231) while remaining unchanged or increasing in normal cells (MCF10A, primary hepatocytes), with the differential being VDAC1-dependent.",
      "testability_score": 7.0,
      "key_variables": [],
      "parameters": [
        {
          "name": "IC50_cancer_generic_lipo",
          "range": "8.0-20.0 \u00b5M",
          "distribution": "uniform"
        },
        {
          "name": "IC50_cancer_mimetic_lipo",
          "range": "2.0-8.0 \u00b5M",
          "distribution": "uniform"
        },
        {
          "name": "IC50_normal_generic_lipo",
          "range": "15.0-40.0 \u00b5M",
          "distribution": "uniform"
        },
        {
          "name": "IC50_normal_mimetic_lipo",
          "range": "20.0-50.0 \u00b5M",
          "distribution": "uniform"
        },
        {
          "name": "liposome_diameter",
          "range": "80.0-150.0 nm",
          "distribution": "uniform"
        },
        {
          "name": "encapsulation_efficiency",
          "range": "60.0-95.0 %",
          "distribution": "uniform"
        },
        {
          "name": "selectivity_index_target",
          "range": "3.0-15.0 fold",
          "distribution": "log-normal"
        }
      ],
      "monte_carlo": {
        "effect_size": 0.7132,
        "power": 1.0,
        "converged": "True",
        "outcome_stats": {
          "effect_magnitude": {
            "mean": 0.49909666245701906,
            "std": 0.10400671611305971,
            "median": 0.4973266418192717,
            "ci_lower": 0.29735486282849843,
            "ci_upper": 0.6971659270465291,
            "min": 0.2201938955397335,
            "max": 0.7515278706916007
          }
        }
      }
    }
  ],
  "simulations": {
    "n_hypotheses_simulated": 4,
    "total_iterations": 1200,
    "llm_calls": 0,
    "results": [
      {
        "hypothesis_id": "H1",
        "n_iterations": 300,
        "effect_size": 0.8708,
        "power": 1.0,
        "converged": "True",
        "parameters": {
          "cardiolipin_mol_percent": {
            "mean": 12.16633720673229,
            "std": 7.245549425263572,
            "median": 11.975104539610424,
            "ci_lower": 0.6922426099388946,
            "ci_upper": 24.104328613404743,
            "min": 0.1840567437751378,
            "max": 24.809389101395926
          },
          "gating_shift_mV": {
            "mean": 15.106392302569354,
            "std": 5.676350895835356,
            "median": 15.269621147971726,
            "ci_lower": 5.722174009611933,
            "ci_upper": 24.602408447200986,
            "min": 5.108596682574009,
            "max": 24.982094609484772
          },
          "CBD_Kd_POPC": {
            "mean": 10.983197460798262,
            "std": 1.7869882209743453,
            "median": 11.012627893137179,
            "ci_lower": 8.102582401827055,
            "ci_upper": 13.90415962308949,
            "min": 8.00739837507145,
            "max": 13.99246022040059
          },
          "CBD_Kd_CL": {
            "mean": 5.067348008061408,
            "std": 1.7499144760378715,
            "median": 4.945596085709714,
            "ci_lower": 2.255542664230625,
            "ci_upper": 7.901136162837792,
            "min": 2.003112464994233,
            "max": 7.996531455345127
          },
          "bilayer_capacitance": {
            "mean": 0.6007520965958376,
            "std": 0.07104067079581759,
            "median": 0.5993522211298746,
            "ci_lower": 0.4594720056366978,
            "ci_upper": 0.7414690410321679,
            "min": 0.4029587450436621,
            "max": 0.7807163684812218
          }
        }
      },
      {
        "hypothesis_id": "H2",
        "n_iterations": 300,
        "effect_size": 0.9767,
        "power": 1.0,
        "converged": "True",
        "parameters": {
          "cholesterol_mol_percent_healthy": {
            "mean": 5.491386463799144,
            "std": 1.425356567662941,
            "median": 5.474467563598466,
            "ci_lower": 3.131790219184463,
            "ci_upper": 7.85546875299555,
            "min": 3.015750763826693,
            "max": 7.989408721370602
          },
          "cholesterol_mol_percent_cancer": {
            "mean": 19.958055945406397,
            "std": 2.8563386987565385,
            "median": 20.03086662708039,
            "ci_lower": 15.212352554311575,
            "ci_upper": 24.677984718824778,
            "min": 15.022204970641251,
            "max": 24.95582661515631
          },
          "CBD_Kd_low_chol": {
            "mean": 11.506285392554657,
            "std": 1.999240653386984,
            "median": 11.360150624300402,
            "ci_lower": 8.238365125243591,
            "ci_upper": 14.843137162524709,
            "min": 8.117812192439443,
            "max": 14.98489428580729
          },
          "CBD_Kd_high_chol": {
            "mean": 5.049746988757539,
            "std": 1.7862743646982777,
            "median": 5.192682382451334,
            "ci_lower": 2.1338632108555613,
            "ci_upper": 7.833441869144363,
            "min": 2.0337996054893024,
            "max": 7.98797968876466
          },
          "CBD_logP": {
            "mean": 6.310174444205871,
            "std": 0.29849930267190067,
            "median": 6.325772723879746,
            "ci_lower": 5.839775239243687,
            "ci_upper": 6.784615578320034,
            "min": 5.804440215423909,
            "max": 6.797628752074644
          },
          "partition_coefficient_ratio": {
            "mean": 2.7838276611940955,
            "std": 0.7068560186827318,
            "median": 2.7407447702451035,
            "ci_lower": 1.5,
            "ci_upper": 4.0,
            "min": 1.5,
            "max": 4.0
          }
        }
      },
      {
        "hypothesis_id": "H3",
        "n_iterations": 300,
        "effect_size": 0.806,
        "power": 1.0,
        "converged": "True",
        "parameters": {
          "cholesterol_threshold": {
            "mean": 16.874490561988885,
            "std": 2.8826639876805626,
            "median": 16.624847990955757,
            "ci_lower": 12.375102424945823,
            "ci_upper": 21.726536206817958,
            "min": 12.054953260185524,
            "max": 21.953856862104132
          },
          "olesoxime_Kd_high_chol": {
            "mean": 2.6801379723766248,
            "std": 1.3216510024669692,
            "median": 2.619727686872735,
            "ci_lower": 0.6122077752226437,
            "ci_upper": 4.8646285776825735,
            "min": 0.505788130808366,
            "max": 4.96752287449542
          },
          "olesoxime_Kd_low_chol": {
            "mean": 53.37235182058823,
            "std": 26.583617447293715,
            "median": 51.478035667075645,
            "ci_lower": 12.353405464949736,
            "ci_upper": 97.42275740403521,
            "min": 10.299143373461863,
            "max": 99.53191820553533
          },
          "M\u03b2CD_concentration": {
            "mean": 5.754623640299745,
            "std": 2.2540717146102307,
            "median": 5.501030255392617,
            "ci_lower": 2.1717205129843635,
            "ci_upper": 9.6137342457262,
            "min": 2.0034612043686604,
            "max": 9.976479216230455
          },
          "cholesterol_depletion_efficiency": {
            "mean": 61.75408938463106,
            "std": 12.021727662660957,
            "median": 63.596794954991786,
            "ci_lower": 41.477292792553804,
            "ci_upper": 79.02239055081984,
            "min": 40.05090031344772,
            "max": 79.79220808867754
          },
          "cytochrome_c_release_inhibition": {
            "mean": 46.39797731941774,
            "std": 25.889767044949537,
            "median": 47.63178384101833,
            "ci_lower": 2.9601228875813557,
            "ci_upper": 88.32418805114878,
            "min": 0.004089140852056028,
            "max": 89.99727022591199
          }
        }
      },
      {
        "hypothesis_id": "H4",
        "n_iterations": 300,
        "effect_size": 0.7132,
        "power": 1.0,
        "converged": "True",
        "parameters": {
          "IC50_cancer_generic_lipo": {
            "mean": 14.129272693039926,
            "std": 3.446302054440899,
            "median": 14.048718154382346,
            "ci_lower": 8.241880056003478,
            "ci_upper": 19.80051255301561,
            "min": 8.000650309757702,
            "max": 19.975349374534094
          },
          "IC50_cancer_mimetic_lipo": {
            "mean": 5.008022047182737,
            "std": 1.7567177044617643,
            "median": 5.183931782884786,
            "ci_lower": 2.1142937332693137,
            "ci_upper": 7.646672283145389,
            "min": 2.0166426996060443,
            "max": 7.943241498233652
          },
          "IC50_normal_generic_lipo": {
            "mean": 27.147228239034938,
            "std": 7.289707826352861,
            "median": 27.287063110803643,
            "ci_lower": 15.789494911416728,
            "ci_upper": 38.92185204400378,
            "min": 15.156144786433837,
            "max": 39.946999342348214
          },
          "IC50_normal_mimetic_lipo": {
            "mean": 34.56375874117236,
            "std": 8.753518010118317,
            "median": 34.03266227474913,
            "ci_lower": 20.9278192111391,
            "ci_upper": 49.07093635238666,
            "min": 20.273263596104215,
            "max": 49.73339568929928
          },
          "liposome_diameter": {
            "mean": 113.97026364882645,
            "std": 19.90769230981085,
            "median": 116.46151894153232,
            "ci_lower": 81.21552889073634,
            "ci_upper": 146.18930904398144,
            "min": 80.0014287665043,
            "max": 149.90813643980928
          },
          "encapsulation_efficiency": {
            "mean": 77.17716065854778,
            "std": 10.187949764893592,
            "median": 77.22386041469218,
            "ci_lower": 60.957489842068725,
            "ci_upper": 94.01645082598203,
            "min": 60.06152765490157,
            "max": 94.92386778081935
          },
          "selectivity_index_target": {
            "mean": 9.409843813620428,
            "std": 2.612360595732426,
            "median": 9.296273937444282,
            "ci_lower": 5.01727629209985,
            "ci_upper": 15.0,
            "min": 3.093058105614932,
            "max": 15.0
          }
        }
      }
    ]
  },
  "protocols": [
    {
      "hypothesis_id": "H1",
      "prediction": "IF VDAC1 is reconstituted in planar lipid bilayers containing 10-20 mol% cardiolipin (vs pure POPC), THEN voltage-gating midpoint shifts by 10-20 mV toward more negative potentials AND CBD Kd decreases by \u22652-fold (from ~11 \u00b5M to \u22645.5 \u00b5M).",
      "protocol": "Reconstitute purified human VDAC1 into planar lipid bilayers (POPC alone vs POPC:CL 85:15). Measure single-channel conductance and voltage-gating curves (\u00b160 mV triangular ramps, n\u226530 insertions per condition). Determine CBD Kd via",
      "dose_ranges": {
        "CBD": {
          "doses": [
            0.1,
            0.5,
            1.0,
            3.0,
            5.0,
            10.0,
            20.0,
            50.0
          ],
          "unit": "\u00b5M"
        }
      },
      "readouts": [
        "Single-channel electrophysiology (conductance",
        "open probability",
        "V\u2080)",
        "MST binding curves",
        "DLS for nanodisc QC"
      ],
      "controls": [
        "POPC-only bilayers",
        "heat-denatured VDAC1",
        "CL-containing bilayers without VDAC (membrane-only CBD partitioning)",
        "VDAC2 as isoform control",
        "---",
        "##"
      ],
      "expected_outcome": "CL-containing bilayers show V\u2080 shift of \u221212 to \u221218 mV; CBD IC\u2085\u2080 for conductance inhibition drops from ~11 \u00b5M to ~4-6 \u00b5M; MST confirms Kd shift.",
      "null_outcome": "No significant V\u2080 shift (<5 mV) and CBD Kd remains 9-13 \u00b5M regardless of CL content."
    },
    {
      "hypothesis_id": "H2",
      "prediction": "IF VDAC1 is embedded in nanodiscs with 20 mol% cholesterol (cancer-mimetic) vs 5 mol% (healthy-mimetic), THEN the apparent CBD-VDAC1 Kd decreases from ~11 \u00b5M to 3-6 \u00b5M due to enhanced local partitioning, placing it within the 1-10 \u00b5M therapeutic window.",
      "protocol": "Assemble MSP1D1-based nanodiscs with POPC + 5 mol% or 20 mol% cholesterol, each containing single VDAC1. Measure CBD binding by MST (label VDAC1 with RED-NHS) and independently by ITC. Quantify free vs membrane-partitioned CBD using equilibrium dialysis with \u00b3H-CBD or LC-MS/MS. Parallel SPR with VDAC1-nanodiscs immobilized on L1 chip. Timeline: 6-8 weeks.",
      "dose_ranges": {
        "CBD": {
          "doses": [
            0.3,
            1.0,
            3.0,
            5.0,
            10.0,
            15.0,
            25.0,
            50.0
          ],
          "unit": "\u00b5M"
        }
      },
      "readouts": [
        "MST (Kd)",
        "ITC (Kd",
        "\u0394H",
        "stoichiometry)",
        "SPR (kon",
        "koff",
        "KD)",
        "LC-MS/MS (free CBD quantification)",
        "laurdan GP (membrane order)"
      ],
      "controls": [
        "Empty nanodiscs (no VDAC1) for partitioning-only measurement",
        "cholesterol-free nanodiscs",
        "VDAC1 in detergent micelles (lipid-free Kd reference)",
        "ergosterol substitution (sterol specificity)",
        "---",
        "##"
      ],
      "expected_outcome": "Apparent Kd drops 2-3 fold in 20% cholesterol nanodiscs; equilibrium dialysis confirms 2-3\u00d7 higher CBD retention in cholesterol-rich nanodiscs; SPR kon increases while koff is unchanged.",
      "null_outcome": "Kd values within 20% of each other across cholesterol conditions; or Kd increases* in high-cholesterol nanodiscs (supporting claims [5]/[9] that cholesterol sequesters CBD away from VDAC)."
    },
    {
      "hypothesis_id": "H3",
      "prediction": "IF OMM cholesterol is depleted below ~15 mol% (via M\u03b2CD treatment or low-cholesterol nanodiscs), THEN olesoxime-VDAC1 binding affinity drops by \u22655-fold AND neuroprotective activity (prevention of cytochrome c release) is abolished.",
      "protocol": "(A) Biophysical: Measure olesoxime binding to VDAC1 in nanodiscs with 5, 10, 15, 20, 25, 30 mol% cholesterol by MST and ITC, generating a full cholesterol-dependence curve. (B) Cellular: Treat SH-SY5Y neurons with 5 mM M\u03b2CD (titrated to achieve 40-70% cholesterol depletion, verified by Amplex Red), then challenge with staurosporine (1 \u00b5M) \u00b1 olesoxime (1-30 \u00b5M). Measure cytochrome c release (ELISA from cytosolic fraction), \u0394\u03a8m (TMRE), and viability (CellTiter-Glo). Include cholesterol repletion rescue arm. Timeline: 10-12 weeks.",
      "dose_ranges": {
        "Olesoxime": {
          "doses": [
            0.3,
            1.0,
            3.0,
            10.0,
            30.0
          ],
          "unit": "\u00b5M;"
        },
        "M\u03b2CD": {
          "doses": [
            2.0,
            5.0,
            10.0
          ],
          "unit": "mM;"
        },
        "Staurosporine": {
          "doses": [
            1.0
          ],
          "unit": "\u00b5M;"
        },
        "M\u03b2CD repletion": {
          "doses": [
            0.5,
            1.0,
            2.0
          ],
          "unit": "mM"
        }
      },
      "readouts": [
        "MST/ITC (Kd)",
        "Amplex Red (cholesterol quantification)",
        "TMRE (\u0394\u03a8m)",
        "cytochrome c ELISA",
        "CellTiter-Glo (viability)",
        "filipin staining (cholesterol imaging)"
      ],
      "controls": [
        "Vehicle (DMSO)",
        "M\u03b2CD alone (toxicity control)",
        "olesoxime without stressor",
        "CRAC-mutant olesoxime analog (if available)",
        "cholesterol repletion rescue",
        "VDAC1-knockdown cells (target validation)",
        "---",
        "##"
      ],
      "expected_outcome": "Sigmoidal cholesterol-dependence curve for olesoxime binding with inflection at ~15-20 mol%; M\u03b2CD-treated neurons show complete loss of olesoxime neuroprotection; cholesterol repletion restores protection.",
      "null_outcome": "Olesoxime binds VDAC1 with similar affinity (within 2-fold) regardless of cholesterol content; M\u03b2CD-treated neurons still protected by olesoxime."
    },
    {
      "hypothesis_id": "H4",
      "prediction": "IF CBD is delivered via liposomes matching cancer OMM composition (20 mol% cholesterol, 5 mol% CL, 75% POPC) vs generic liposomes (100% POPC), THEN IC\u2085\u2080 for cancer cell killing decreases by \u22653-fold in cancer lines (HCT116, MDA-MB-231) while remaining unchanged or increasing in normal cells (MCF10A, primary hepatocytes), with the differential being VDAC1-dependent.",
      "protocol": "Prepare liposomes by thin-film hydration + extrusion (100 nm): (i) cancer-mimetic (POPC:Chol:CL 75:20:5), (ii) healthy-mimetic (POPC:Chol:CL 90:5:5), (iii) generic (POPC only), all loaded with CBD. Characterize by DLS, zeta potential, HPLC (encapsulation). Treat HCT116, M",
      "dose_ranges": {},
      "readouts": [],
      "controls": [],
      "expected_outcome": "",
      "null_outcome": ""
    }
  ],
  "budget": {
    "s1_calls": 5,
    "s2_calls": 0,
    "verify_calls": 10,
    "gate_calls": 1,
    "s4_calls": 1,
    "s5_calls": 0,
    "total_calls": 17,
    "budget_target": "92-142 calls"
  },
  "audit_trail": {
    "session_seed": 1771007665,
    "s2_rounds": [],
    "s3_gate": {
      "stage": "S3",
      "passed": true,
      "convergence_score": 0.9512,
      "convergence_threshold": 0.85,
      "convergence_pass": true,
      "jaccard": 0.92,
      "jaccard_threshold": 0.85,
      "jaccard_pass": true,
      "type_01_ratio": 1.0,
      "type_01_threshold": 0.75,
      "type_pass": true,
      "cosine": 0.9512,
      "jsd": 0.0655,
      "kappa": 0.93,
      "type_distribution": {
        "0": 0.8235294117647058,
        "1": 0.17647058823529413,
        "2": 0.0,
        "3": 0.0
      }
    },
    "final_claims": [
      {
        "statement": "Cardiolipin at OMM-IMM contact sites stabilizes VDAC in a partially closed state, altering both gating voltage-dependence and the accessibility of CBD's binding site.",
        "type": 2,
        "confidence": 0.55,
        "mechanism": "Cardiolipin's negative charge and cone-shape geometry modify VDAC barrel lipid-facing residues and electrostatic surface potential, shifting voltage-gating thresholds by ~10-20 mV as shown in reconstituted systems.",
        "falsifiable_by": "Electrophysiology of VDAC in cardiolipin-free vs cardiolipin-containing planar bilayers showing no gating shift and unchanged CBD Kd.",
        "model": "claude"
      },
      {
        "statement": "Cancer cell OMM cholesterol enrichment (typically 2-4\u00d7 vs normal) increases membrane partitioning of CBD, raising local membrane concentration and reducing the apparent Kd from ~11 \u00b5M (bulk) to an effective ~3-6 \u00b5M at the VDAC interface.",
        "type": 3,
        "confidence": 0.4,
        "mechanism": "Cholesterol-rich membranes increase the partition coefficient of high-logP compounds; for CBD (logP 6.3), a 2-3\u00d7 cholesterol increase could raise local [CBD] ~2-3 fold via enhanced hydrophobic retention, but cholesterol also rigidifies the membrane, potentially occluding binding grooves.",
        "falsifiable_by": "SPR or MST measurement of CBD-VDAC Kd in nanodiscs with defined cholesterol content (5% vs 20% mol) showing no Kd shift.",
        "model": "claude"
      },
      {
        "statement": "Olesoxime efficacy is membrane-cholesterol-dependent because its CRAC motif mediates initial membrane anchoring; in low-cholesterol membranes (neurons under stress), olesoxime partitions less efficiently, explaining variable neuroprotective outcomes across trials.",
        "type": 2,
        "confidence": 0.5,
        "mechanism": "CRAC-motif-cholesterol interaction serves as a prerequisite membrane docking step before lateral diffusion to VDAC; cholesterol depletion (e.g., M\u03b2CD) should abolish olesoxime-VDAC interaction.",
        "falsifiable_by": "Olesoxime binding to VDAC measured \u00b1 M\u03b2CD treatment showing cholesterol-independent binding.",
        "model": "claude"
      },
      {
        "statement": "Liposomes engineered with cancer-mimetic lipid compositions (high cholesterol, low cardiolipin) would enhance CBD delivery to cancer OMM, potentially achieving VDAC-selective concentrations within the 1-10 \u00b5M therapeutic window while remaining below TRPV1/PPAR\u03b3 activation thresholds.",
        "type": 3,
        "confidence": 0.3,
        "mechanism": "Fusogenic liposomes matching target OMM composition preferentially transfer lipophilic cargo via membrane fusion; composition matching reduces thermodynamic barrier to transfer.",
        "falsifiable_by": "In vitro cytotoxicity assay showing no differential potency of CBD-loaded cancer-mimetic vs generic liposomes on cancer vs normal cells. \u2500\u2500\u2500",
        "model": "claude"
      },
      {
        "statement": "Cardiolipin at OMM contact sites increases VDAC\u2019s open probability and reduces CBD binding affinity by ~2-fold.",
        "type": 2,
        "confidence": 0.7,
        "mechanism": "CL\u2019s negative curvature stabilizes VDAC\u2019s open state via electrostatic interactions with basic residues, competing with CBD\u2019s hydrophobic binding pocket.",
        "falsifiable_by": "Reconstitution assays showing CBD Kd >20 \u00b5M in CL-enriched liposomes vs. 11 \u00b5M in control (Rimmerman baseline).",
        "model": "mistral"
      },
      {
        "statement": "Cancer mitochondria\u2019s elevated cholesterol/phospholipid ratio increases CBD\u2019s effective Kd by 3\u20135 \u00b5M due to reduced membrane partitioning.",
        "type": 1,
        "confidence": 0.8,
        "mechanism": "Cholesterol rigidifies membranes, lowering CBD\u2019s free concentration at VDAC by ~30% (logP-dependent sequestration).",
        "falsifiable_by": "Kd measurements in cancer vs. healthy OMM vesicles showing CBD Kd >14 \u00b5M in high-cholesterol conditions.",
        "model": "mistral"
      },
      {
        "statement": "Olesoxime\u2019s neuroprotection requires >20 mol% cholesterol in OMM; below this threshold, it becomes neutral or cytotoxic.",
        "type": 3,
        "confidence": 0.5,
        "mechanism": "Cholesterol\u2019s CRAC motif binding may allosterically stabilize VDAC\u2019s closed state, preventing cytochrome c release.",
        "falsifiable_by": "Olesoxime dose-response curves in neurons with cholesterol-depleted OMM (e.g., M\u03b2CD-treated) showing loss of protection at <15 mol% cholesterol.",
        "model": "mistral"
      },
      {
        "statement": "Liposomes with 1:1 CL/cholesterol enhance CBD potency in cancer cells (Kd ~5 \u00b5M) but reduce it in healthy cells (Kd ~20 \u00b5M).",
        "type": 2,
        "confidence": 0.6,
        "mechanism": "CL-rich liposomes fuse preferentially with cancer OMM (high curvature), increasing local CBD concentration, while cholesterol-rich liposomes stabilize healthy OMM.",
        "falsifiable_by": "Cell-type-specific Kd measurements with lipid-tailored liposomes showing opposite potency shifts. --- ### \u2500\u2500\u2500",
        "model": "mistral"
      },
      {
        "statement": "Cardiolipin at OMM contact sites stabilizes VDAC in open conformation, potentially enhancing CBD binding.",
        "type": 2,
        "confidence": 0.8,
        "mechanism": "CL directly binds VDAC C-terminal helix, promoting monomeric/open states that expose ligand sites.",
        "falsifiable_by": "No Kd shift for CBD in CL-enriched vs PC liposomes via SPR.",
        "model": "grok"
      },
      {
        "statement": "Cancer OMM higher chol/PL ratio increases membrane order, reducing effective CBD concentration at VDAC due to sequestration.",
        "type": 3,
        "confidence": 0.6,
        "mechanism": "Lipophilic CBD (logP 6.3, Kd=11\u03bcM) partitions preferentially into ordered chol-rich domains, lowering free [CBD] for VDAC.",
        "falsifiable_by": "Identical CBD-VDAC Kd in cancer-mimic vs healthy-mimic liposomes by ITC.",
        "model": "grok"
      },
      {
        "statement": "Olesoxime VDAC binding/efficacy depends on OMM cholesterol, enabling neuroprotection in chol-high healthy mitochondria.",
        "type": 2,
        "confidence": 0.7,
        "mechanism": "CRAC motif requires chol for membrane insertion/VDAC stabilization; low chol (e.g., cancer) abolishes affinity.",
        "falsifiable_by": "No potency difference in chol-depleted vs native mito liposomes for neuroprotection assays.",
        "model": "grok"
      },
      {
        "statement": "Lipid-specific liposomes can enhance VDAC modulator potency >2x in cancer cells via chol-targeted delivery.",
        "type": 3,
        "confidence": 0.5,
        "mechanism": "Cancer OMM-like chol/PL liposomes increase local modulator partitioning, shifting effective Kd into therapeutic window (1-10\u03bcM).",
        "falsifiable_by": "No potency gain in vivo for chol-mimic liposomes vs plain in cancer xenografts. \u2500\u2500\u2500",
        "model": "grok"
      },
      {
        "statement": "The higher cholesterol content in cancer cell OMM increases the local concentration of highly lipophilic drugs like CBD (logP 6.3), lowering the effective VDAC1-CBD Kd below the reported 11.0 uM and making VDAC a more prominent target within the therapeutic window [1.0, 10.0] uM specifically in cancer cells.",
        "type": 2,
        "confidence": 0.8,
        "mechanism": "Increased membrane cholesterol enhances the partitioning of hydrophobic molecules into the OMM, elevating the drug concentration in the direct vicinity of VDAC and thus increasing the apparent binding affinity.",
        "falsifiable_by": "Measuring CBD-VDAC1 binding in proteoliposomes with low (healthy) vs. high (cancer-like) cholesterol content and finding no significant change in the measured Kd.",
        "model": "gemini"
      },
      {
        "statement": "Olesoxime's therapeutic activity is strictly dependent on a narrow range of membrane cholesterol concentration, making it neuroprotective in healthy neurons but inert in cells with dysregulated cholesterol metabolism (e.g., certain cancers or neurodegenerative states).",
        "type": 1,
        "confidence": 0.9,
        "mechanism": "Olesoxime's cholesterol-recognition amino acid consensus (CRAC) motif requires a direct interaction with a cholesterol molecule to achieve the correct conformation for high-affinity binding to VDAC, and this ternary complex is unstable outside an optimal cholesterol concentration range.",
        "falsifiable_by": "Demonstrating that olesoxime retains VDAC binding and cytoprotective activity in cells that have been artificially depleted of or overloaded with membrane cholesterol.",
        "model": "gemini"
      },
      {
        "statement": "Liposomes formulated with a cancer-like lipid profile (e.g., high cholesterol, low cardiolipin) will deliver VDAC modulators to cancer mitochondria more effectively than liposomes with a healthy lipid profile, increasing drug potency.",
        "type": 2,
        "confidence": 0.75,
        "mechanism": "Enhanced membrane fusion and/or lipid exchange between vesicles and the OMM is favored when their lipid compositions are similar, leading to more efficient drug transfer.",
        "falsifiable_by": "Showing that the IC50 of a VDAC-targeting drug delivered by cancer-mimicking vs. healthy-mimicking liposomes is identical in a cancer cell line. \u2500\u2500\u2500",
        "model": "gemini"
      },
      {
        "statement": "Cardiolipin at OMM contact sites alters VDAC gating dynamics, likely promoting a conformation with higher affinity for certain ligands (e.g., olesoxime) but not necessarily CBD.",
        "type": 2,
        "confidence": 0.7,
        "mechanism": "Cardiolipin's negative charge and conical shape distort local membrane curvature and electrostatics, stabilizing specific VDAC oligomeric states or tilts.",
        "falsifiable_by": "In vitro electrophysiology showing identical VDAC gating in pure PC vs PC+cardiolipin membranes.",
        "model": "deepseek"
      },
      {
        "statement": "Increased OMM cholesterol in some cancers significantly raises the effective local concentration of CBD at VDAC, lowering its apparent functional Kd below the measured 11 \u00b5M.",
        "type": 1,
        "confidence": 0.8,
        "mechanism": "Higher cholesterol increases membrane order and partition coefficient for lipophilic CBD (logP 6.3), enriching it in the OMM and increasing probability of VDAC interaction.",
        "falsifiable_by": "Measuring CBD binding to VDAC in lipid nanodiscs with high vs low cholesterol showing no Kd difference.",
        "model": "deepseek"
      },
      {
        "statement": "Olesoxime's neuroprotective effect requires an optimal, intermediate OMM cholesterol level, explaining its cell-type-specific activity.",
        "type": 2,
        "confidence": 0.75,
        "mechanism": "Too little cholesterol prevents olesoxime's membrane recruitment via its cholesterol-recognition motif; too much cholesterol competitively inhibits its specific binding site on VDAC.",
        "falsifiable_by": "Olesoxime showing identical VDAC binding and cytoprotection in cells with very high and very low membrane cholesterol. \u2500\u2500\u2500",
        "model": "deepseek"
      }
    ]
  }
}